• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

终末期肾衰竭患者血液透析对亚胺培南和西司他丁的清除作用。

Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure.

作者信息

Konishi K, Suzuki H, Saruta T, Hayashi M, Deguchi N, Tazaki H, Hisaka A

机构信息

Department of Medicine, School of Medicine, Keio University, Tokyo, Japan.

出版信息

Antimicrob Agents Chemother. 1991 Aug;35(8):1616-20. doi: 10.1128/AAC.35.8.1616.

DOI:10.1128/AAC.35.8.1616
PMID:1929334
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC245229/
Abstract

The removal of imipenem and cilastatin by hemodialysis was studied in 14 (for imipenem) and 6 (for cilastatin) subjects. Following intravenous infusion of imipenem and cilastatin at a combined concentration of 10 mg/kg of body weight, drug levels in plasma were determined serially during off- and on-hemodialysis periods, which were 2 and 4 h, respectively. The biexponential decay of the drug levels in plasma was evident in each subject for both imipenem and cilastatin. Hemodialysis accelerated the elimination of both imipenem and cilastatin: the mean elimination-phase half-life of imipenem was shortened from 200 to 78 min, and that of cilastatin was shortened from 445 to 115 min. Hemodialysis clearance of imipenem and cilastatin was calculated by five different methods, each with intrinsic assumptions. The mean hemodialysis clearance of imipenem was estimated to be 74.08 +/- 13.29 ml/min, and that of cilastatin was estimated to be 65.0 +/- 8.6 ml/min, after consideration of various methodological limitations. It was estimated that in a hypothetical anephric patient weighing 60 kg, a 4-h hemodialysis treatment would remove 54.8% of the imipenem and 62.9% of the cilastatin present in the body at the start of dialysis.

摘要

在14名受试者(针对亚胺培南)和6名受试者(针对西司他丁)中研究了血液透析对亚胺培南和西司他丁的清除情况。以10mg/kg体重的联合浓度静脉输注亚胺培南和西司他丁后,分别在血液透析前2小时和透析期间4小时连续测定血浆中的药物水平。亚胺培南和西司他丁在每个受试者的血浆中均呈现双指数衰减。血液透析加速了亚胺培南和西司他丁的清除:亚胺培南的平均消除相半衰期从200分钟缩短至78分钟,西司他丁的平均消除相半衰期从445分钟缩短至115分钟。通过五种不同方法计算了亚胺培南和西司他丁的血液透析清除率,每种方法都有其内在假设。考虑到各种方法学限制后,亚胺培南的平均血液透析清除率估计为74.08±13.29ml/min,西司他丁的平均血液透析清除率估计为65.0±8.6ml/min。据估计,在一名假设体重60kg的无肾患者中,4小时的血液透析治疗将清除透析开始时体内54.8%的亚胺培南和62.9%的西司他丁。

相似文献

1
Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure.终末期肾衰竭患者血液透析对亚胺培南和西司他丁的清除作用。
Antimicrob Agents Chemother. 1991 Aug;35(8):1616-20. doi: 10.1128/AAC.35.8.1616.
2
[Clinical pharmacokinetics of an imipenem-cilastatin combination].
Presse Med. 1990 Apr 4;19(13):598-605.
3
Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.
J Antimicrob Chemother. 1991 Feb;27(2):225-32. doi: 10.1093/jac/27.2.225.
4
Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.
Clin Nephrol. 1994 Sep;42(3):193-7.
5
Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
Nephrol Dial Transplant. 1989;4(7):640-5.
6
Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill.亚胺培南与西司他丁在重症患者持续静静脉血液透析期间的药代动力学
ASAIO J. 1997 Jan-Feb;43(1):84-8.
7
The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.亚胺培南(硫霉素-甲脒)和肾脏脱氢肽酶抑制剂西司他丁钠在正常受试者和肾衰竭患者中的药代动力学。
Br J Clin Pharmacol. 1984 Aug;18(2):183-93. doi: 10.1111/j.1365-2125.1984.tb02451.x.
8
Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration.
J Antimicrob Chemother. 1990 Jul;26(1):91-8. doi: 10.1093/jac/26.1.91.
9
Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis.亚胺培南-西司他丁在持续性非卧床腹膜透析的肾功能不全患者中的药代动力学。
Antimicrob Agents Chemother. 1988 Apr;32(4):530-4. doi: 10.1128/AAC.32.4.530.
10
A serial application study on twice daily dose of imipenem/cilastatin in patients undergoing slow hemodialysis.对接受缓慢血液透析患者每日两次剂量亚胺培南/西司他丁的系列应用研究。
Nephron. 1994;68(3):406-7. doi: 10.1159/000188421.

引用本文的文献

1
Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy.危重症患者接受新型创新肾脏替代治疗时的抗生素剂量推荐。
BMC Nephrol. 2024 Feb 27;25(1):73. doi: 10.1186/s12882-024-03469-2.
2
Optimization of anti-infective dosing regimens during online haemodiafiltration.在线血液透析滤过期间抗感染给药方案的优化
Clin Kidney J. 2017 Apr;10(2):282-290. doi: 10.1093/ckj/sfx009. Epub 2017 Mar 29.
3
Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.重症监护中的抗菌药物给药:脓毒症的药代动力学、疾病程度及药效学
Clin Pharmacokinet. 2006;45(8):755-73. doi: 10.2165/00003088-200645080-00001.
4
Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.间歇性血液透析和连续性肾脏替代治疗期间的药物剂量:儿科患者的特殊考量
Paediatr Drugs. 2004;6(1):45-65. doi: 10.2165/00148581-200406010-00004.
5
Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.美罗培南在肾衰竭患者和接受肾脏替代治疗患者中的药代动力学。
Clin Pharmacokinet. 2000 Oct;39(4):271-9. doi: 10.2165/00003088-200039040-00003.
6
Comparative pharmacokinetics of the carbapenems: clinical implications.碳青霉烯类药物的比较药代动力学:临床意义。
Clin Pharmacokinet. 2000 Sep;39(3):185-201. doi: 10.2165/00003088-200039030-00002.
7
Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.亚胺培南-西司他丁在接受持续静静脉血液滤过的危重症患者中的药代动力学
Antimicrob Agents Chemother. 1997 Dec;41(12):2640-5. doi: 10.1128/AAC.41.12.2640.
8
Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis.接受缓慢血液透析的危重症患者单剂量静脉注射阿米卡星的药代动力学
Intensive Care Med. 1995 Apr;21(4):348-51. doi: 10.1007/BF01705414.

本文引用的文献

1
The assessment of fractional drug removal by extracorporeal dialysis.体外透析对药物清除分数的评估。
Biopharm Drug Dispos. 1982 Apr-Jun;3(2):165-73. doi: 10.1002/bdd.2510030207.
2
The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.亚胺培南(硫霉素-甲脒)和肾脏脱氢肽酶抑制剂西司他丁钠在正常受试者和肾衰竭患者中的药代动力学。
Br J Clin Pharmacol. 1984 Aug;18(2):183-93. doi: 10.1111/j.1365-2125.1984.tb02451.x.
3
Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.接受血液透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1984 Jan-Feb;9(1):42-66. doi: 10.2165/00003088-198409010-00003.
4
Photoelectric measurement of blood flow during hemodialysis.血液透析期间血流的光电测量。
Kidney Int. 1973 Mar;3(3):190-2. doi: 10.1038/ki.1973.28.
5
Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency.
Am J Med. 1985 Jun 7;78(6A):54-61. doi: 10.1016/0002-9343(85)90102-0.
6
Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis.亚胺培南/西司他丁在终末期肾病长期血液透析患者中的多剂量研究。
Am J Med. 1985 Jun 7;78(6A):113-6. doi: 10.1016/0002-9343(85)90112-3.
7
Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.亚胺培南/西司他丁。对其抗菌活性、药代动力学特性及治疗效果的综述。
Drugs. 1987 Mar;33(3):183-241. doi: 10.2165/00003495-198733030-00001.
8
An overview of the pharmacology of imipenem/cilastatin.
J Antimicrob Chemother. 1986 Dec;18 Suppl E:79-92. doi: 10.1093/jac/18.supplement_e.79.
9
Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.赤池信息准则(AIC)在线性药代动力学方程评估中的应用。
J Pharmacokinet Biopharm. 1978 Apr;6(2):165-75. doi: 10.1007/BF01117450.
10
Pharmacokinetic evaluation of hemodialysis in acute drug overdose.
J Pharmacokinet Biopharm. 1978 Oct;6(5):427-42. doi: 10.1007/BF01062724.